Also called: Cagrilintide UK & Lab UK, CagriSema (Semaglutide + Cagrilintide), Cagrilintide-Semaglutide Combination
Cagrilintide is a special chemical that acts like a hormone called amylin found in the human body. It is made in a lab and is often grouped with other weight loss tools, but it works differently than many of them. Scientists study it to see how it helps people control how much they eat. It is mostly looked at by researchers who want to find new ways to help with weight problems. This chemical works by talking to the brain and the stomach.
It helps the stomach empty its food more slowly, which makes a person feel full for a longer time. It also works on the brain to stop the urge to eat. Because it affects both the stomach and the brain, it can lower the amount of food someone wants to eat. This is why it is studied for its ability to help control body weight. Right now, Cagrilintide is still being tested and is not a medicine that people can just get.
It is usually sold only for lab research and not for humans to use yet. Some studies show it might work well when mixed with other drugs, but we are still learning about it. There are some side effects, mostly feeling sick to the stomach. It is important to know that it is not approved for general use by health officials.
Benefits
The benefits people report — backed by research.
You just read the research on Cagrilintide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Timeline
Key moments in Cagrilintide’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions Cagrilintide.
Novo Nordisk's experimental combination therapy CagriSema demonstrated superior weight loss and blood sugar control compared to semaglutide alone in a Phase 3 trial. The drug combines the GLP-1 agonist semaglutide with cagrilintide, an amylin receptor agonist, resulting in a 14.2% reduction in body weight over 68 weeks. These results suggest a potential new standard for treating type 2 diabetes and obesity.
A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.
Wondering how Cagrilintide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.